Esperion (ESPR) Gets a Buy Rating from Stifel Nicolaus

In a report released today, Derek Archila from Stifel Nicolaus maintained a Buy rating on Esperion (ESPR). The company’s shares closed last Tuesday at $30.28, close to its 52-week low of $23.90.

According to, Archila is a 4-star analyst with an average return of 13.2% and a 50.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Apellis Pharmaceuticals.

Esperion has an analyst consensus of Strong Buy, with a price target consensus of $66.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $76.98 and a one-year low of $23.90. Currently, Esperion has an average volume of 688.2K.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESPR in relation to earlier this year. Most recently, in December 2020, Timothy Mayleben, the President & CEO of ESPR bought 10,700 shares for a total of $22,363.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts